首页> 外文会议>Society for Biomaterials annual meeting and exposition >Lyophilized Poly(ethylene glycol-b-(diniethylaminoethyl methacrylate-co-butyl methacrylate))-DNA Nanoparticles for Nonviral Gene Therapy
【24h】

Lyophilized Poly(ethylene glycol-b-(diniethylaminoethyl methacrylate-co-butyl methacrylate))-DNA Nanoparticles for Nonviral Gene Therapy

机译:冻干聚(乙二醇-B-(二乙基氨基乙基甲基丙烯酸甲酯 - 甲基丙烯酸叔丁酯) - 用于非血管基因治疗的DNA纳米粒子

获取原文

摘要

Novel poly(EG-b-(DMAEMA-co-BMA))-pDNA nanoparticles were shown to be stable after lyophilization and incubation in PBS and efficiently transfect cells in vitro. Except for 50L, complexes with N/P ratios of 10 and 20 had smaller sizes after lyophilization than Hpofectamine2000 and PEI and higher transfection efficiency than PEI. The time constants for aggregation determined from the exponential fits provide quantitative evidence for the increased stability of poly(EG-b-(DMAEMA-co-BMA)) complexes compared to Iipofectamine2000 and PEI. Future work will involve incorporating lyophilized poly(EG-b-(DMAEMA-co-BMA))-pDNA nanoparticles into tissue engineering scaffolds for in vivo gene therapy applications.
机译:新型聚(例如 - B-(DMAEMA-(DMAEMA-(DMAEMA-(DMAEMA-(DMAEMA-CO-BMA)) - PDNA纳米颗粒在冻干后稳定,并在PBS中孵育并有效地在体外转染细胞。除了50L之外,冻干后的N / P比率为10和20的复合物比HPofectamine2000和PEI在冻干后的尺寸较小,并比PEI更高的转染效率。与指数拟合拟合确定的聚集的时间常数提供了与IIPOCectamine2000和PEI相比增加了聚(EG-B-(DMAEMA-(DMAEMA-BMA))复合物的稳定性的定量证据。未来的工作将涉及将冻干的聚(EG-B-(DMAEMA-(DMAEMA-(DMAEMA-(DMAEMA-CO-BMA)) - PDNA纳米颗粒掺入组织工程支架中,用于体内基因治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号